valcyte的价格是多少？

The main ingredient of Valganciclovir Hydrochloride Tablets () is valganciclovir hydrochloride. The currently approved indications include induction treatment of CMV retinitis, maintenance treatment of CMV retinitis and prevention of CMV infection in transplant patients. The safety and efficacy of valganciclovir hydrochloride tablets (valcyte) treatment were verified in two different trials: The antiviral effect of valganciclovir hydrochloride tablets (valcyte) was clinically confirmed by the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with valganciclovir hydrochloride tablets (valcyte), and the U.S. Food and Drug Administration (FDA) approved the increased use of valganciclovir hydrochloride tablets (valcyte) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valamciclovir hydrochloride tablets (valcyte) reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) one year after receiving a kidney transplant) (p <0.0001).1.2 The overall safety profile of valcyte does not change when prophylaxis is extended in high-risk renal transplant patients. 

We have learned about the therapeutic effect of valganciclovir hydrochloride tablets (valcyte), so what is the price of valganciclovir hydrochloride tablets (valcyte)? According to Medical Travel, Roche’s Valganciclovir Hydrochloride Tablets () are available in 450mg*60 tablets and are priced at approximately RMB 5,500 in Indian pharmacies. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.